Updates are available Correction dated 2022-04-05

Article History

Accepted: 3 March 2022

First Online: 28 March 2022

Change Date: 5 April 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s11523-022-00877-y

Declarations

:

: Study conception and design: MT, RC, VT. Data acquisition: AP, SG, KPP, DWR, NBH, PJO. Data analysis and interpretation: All authors. Manuscript reviewing and editing: All authors. Manuscript original draft: No authors, see medical writing acknowledgment. All authors reviewed and approved the final draft of the manuscript for publication and agree to be accountable for all aspects of this work.

: This study (NCT00975767) was supported by Mirati Therapeutics Inc. Funding for a professional medical writer with access to the data was provided by Mirati Therapeutics Inc.

: Amita Patnaik reports honoraria from the Texas Society of Clinical Oncology; consulting fees (personal) from Bayer, Daiichi Sankyo, Gilead Sciences, HalioDx, Merck, Novartis, Seattle Genetics, Shenzhen IONOVA Life Sciences, and Silverback Therapeutics; consulting fees (to an immediate family member) from Bristol Meyers Squibb, Genentech/Roche, and Merck; and research funding from Abbvie, Arcus Ventures, Astellas Pharma, Bolt Biotherapeutics, Corvus Pharmaceuticals, Daiichi-Sankyo, Exelixis, Fochon Pharmaceuticals, Five Prime Therapeutics, FortySeven, Gilead Sciences, Infinity Pharmaceuticals, Inova, Klus Pharma, Lilly, Livzon, Merck, Pfizer, Pieris Pharmaceuticals, Plexxikon, Sanofi, Seattle Genetics, Surface Oncology, Symphogen, Syndax, Tesaro, Upsher-Smith, and Viego Therapeutics. Shirish Gadgeel reports consulting fees or honorarium from AstraZeneca, Blueprint Medicines, Bristol Meyers Squibb, Eli Lilly, Genentech-Roche, Janssen, Mirati Therapeutics, Novartis, and Pfizer; support for travel to meetings for study manuscript preparation from Genetech-Roche and Merck; fees for participating in review activities from AstraZeneca; and provision of writing assistance from Genentech-Roche and Pfizer. Kyriakos Papadopoulos reports consulting fees from Bicycle Therapeutics and Turning Point Therapeutics; fees for review activities from Basilea Pharmaceutica; and funding for clinical trial conduct from Abbvie, ADC Therapeutics, Amgen, Bayer, Clithera Biosciences, Daiichi Sankyo, EMD Serono, F-star Therapeutics, Incyte, Jounce Therapeutics, Linnaeus Therapeutics, Loxo Oncology, MabSpace Biosciences, 3D Medicines, MedImmune, Merck, Mersana Therapeutics, Mirati Therapeutics, Pfizer, Peloton Therapeutics, Regeneron Pharmaceuticals, Syros Pharmaceuticals, Tempest Therapeutics, and Treadwell. Drew Rasco reports research funding from Mirati Therapeutics. Naomi Haas has no potential conflicts of interest to disclose. Peter O’Dwyer reports research support from Array Biopharma, AstraZeneca, BBI, Bristol Meyers Squibb, Celgene, Five Prime Therapeutics, FortySeven, Genentech, GSK, H3 Biomedicine, Incyte, Lilly (Imclone), Merck, Minneamrita Therapeutics, Mirati Therapeutics, Novartis, Pfizer, Pharmacyclics (AbbVie), Syndax Pharmaceuticals, and Taiho Pharma; consulting fees from Array Biopharma and Genentech; and expert testimonial fees from Bayer and Lilly. Richard Chao, Hirak Der-Torossian, and Vanessa Tassell report employment and stock ownership for Mirati Therapeutics. Diane Potvin reports employment for Mirati Therapeutics. Demiana Faltaos reports prior employment and stock ownership for Mirati Therapeutics. Manal Tawashi reports prior employment for Mirati Therapeutics.

: Requests for data underlying the findings described in this article are available following reasonable request to the corresponding author.

: Not applicable.

: This study was conducted in accordance with the Declaration of Helsinki, International Conference on Harmonisation Guidelines for Good Clinical Practice, and local regulatory requirements. The study protocol was approved by the Institutional Review Boards at each participating study site.

: Patients provided written, informed consent

: All authors gave final approval of the version to be published.